Conatus Pharmaceuticals Reports Results of CTS-1027 in Preclinical Studies

Conatus Pharmaceuticals Inc. reported positive preclinical results on its lead compound, CTS-1027 in multiple models of hepatitis, an inflammatory liver disease. The results were presented in a poster session at the American Association for the Study of Liver Diseases (AASLD) in Boston, Mass.
Fresh News San Diego/Orange County